A double‐blind placebo‐controlled trial of zonisamide (zonegran) in the treatment of essential tremor
Identifieur interne : 002A70 ( Main/Corpus ); précédent : 002A69; suivant : 002A71A double‐blind placebo‐controlled trial of zonisamide (zonegran) in the treatment of essential tremor
Auteurs : Theresa A. Zesiewicz ; Christopher L. Ward ; Robert A. Hauser ; Juan Sanchez-Ramos ; Joseph F. Staffetti ; Kelly L. SullivanSource :
- Movement Disorders [ 0885-3185 ] ; 2007-01-15.
English descriptors
- KwdEn :
Abstract
Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double‐blind placebo‐controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 ± 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn–Tolosa–Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI‐C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 ± 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (−0.50 ± 0.72 vs. 0.30 ± 0.79 m/s2; P = 0.03). On the CGI‐C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was “minimally improved.” Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.21282
Links to Exploration step
ISTEX:E3463E3594391F8A815E479F37127B652E6B3DA4Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A double‐blind placebo‐controlled trial of zonisamide (zonegran) in the treatment of essential tremor</title><author><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Ward, Christopher L" sort="Ward, Christopher L" uniqKey="Ward C" first="Christopher L." last="Ward">Christopher L. Ward</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Sanchez Amos, Juan" sort="Sanchez Amos, Juan" uniqKey="Sanchez Amos J" first="Juan" last="Sanchez-Ramos">Juan Sanchez-Ramos</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Staffetti, Joseph F" sort="Staffetti, Joseph F" uniqKey="Staffetti J" first="Joseph F." last="Staffetti">Joseph F. Staffetti</name><affiliation><mods:affiliation>Regional Medical Center, Bayonet Pointe, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Sullivan, Kelly L" sort="Sullivan, Kelly L" uniqKey="Sullivan K" first="Kelly L." last="Sullivan">Kelly L. Sullivan</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E3463E3594391F8A815E479F37127B652E6B3DA4</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21282</idno><idno type="url">https://api.istex.fr/document/E3463E3594391F8A815E479F37127B652E6B3DA4/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002A70</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A double‐blind placebo‐controlled trial of zonisamide (zonegran) in the treatment of essential tremor</title><author><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Ward, Christopher L" sort="Ward, Christopher L" uniqKey="Ward C" first="Christopher L." last="Ward">Christopher L. Ward</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Sanchez Amos, Juan" sort="Sanchez Amos, Juan" uniqKey="Sanchez Amos J" first="Juan" last="Sanchez-Ramos">Juan Sanchez-Ramos</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Staffetti, Joseph F" sort="Staffetti, Joseph F" uniqKey="Staffetti J" first="Joseph F." last="Staffetti">Joseph F. Staffetti</name><affiliation><mods:affiliation>Regional Medical Center, Bayonet Pointe, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Sullivan, Kelly L" sort="Sullivan, Kelly L" uniqKey="Sullivan K" first="Kelly L." last="Sullivan">Kelly L. Sullivan</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-01-15">2007-01-15</date><biblScope unit="volume">22</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="279">279</biblScope><biblScope unit="page" to="282">282</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">E3463E3594391F8A815E479F37127B652E6B3DA4</idno><idno type="DOI">10.1002/mds.21282</idno><idno type="ArticleID">MDS21282</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>essential tremor</term><term>zonegran</term><term>zonisamide</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="fr">Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double‐blind placebo‐controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 ± 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn–Tolosa–Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI‐C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 ± 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (−0.50 ± 0.72 vs. 0.30 ± 0.79 m/s2; P = 0.03). On the CGI‐C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was “minimally improved.” Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry. © 2006 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Theresa A. Zesiewicz MD</name><affiliations><json:string>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</json:string><json:string>Department of Neurology, University of South Florida, Tampa, Florida, USA</json:string><json:string>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</json:string><json:string>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</json:string><json:string>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</json:string></affiliations></json:item><json:item><name>Christopher L. Ward LMT</name><affiliations><json:string>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</json:string><json:string>Department of Neurology, University of South Florida, Tampa, Florida, USA</json:string><json:string>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</json:string></affiliations></json:item><json:item><name>Robert A. Hauser MD</name><affiliations><json:string>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</json:string><json:string>Department of Neurology, University of South Florida, Tampa, Florida, USA</json:string><json:string>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</json:string><json:string>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</json:string><json:string>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</json:string></affiliations></json:item><json:item><name>Juan Sanchez‐Ramos MD, PhD</name><affiliations><json:string>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</json:string><json:string>Department of Neurology, University of South Florida, Tampa, Florida, USA</json:string><json:string>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</json:string><json:string>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</json:string></affiliations></json:item><json:item><name>Joseph F. Staffetti MD</name><affiliations><json:string>Regional Medical Center, Bayonet Pointe, University of South Florida, Tampa, Florida, USA</json:string></affiliations></json:item><json:item><name>Kelly L. Sullivan MSPH</name><affiliations><json:string>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</json:string><json:string>Department of Neurology, University of South Florida, Tampa, Florida, USA</json:string><json:string>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>zonegran</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>zonisamide</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>essential tremor</value></json:item></subject><articleId><json:string>MDS21282</json:string></articleId><language><json:string>eng</json:string></language><abstract>Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double‐blind placebo‐controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 ± 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn–Tolosa–Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI‐C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 ± 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (−0.50 ± 0.72 vs. 0.30 ± 0.79 m/s2; P = 0.03). On the CGI‐C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was “minimally improved.” Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry. © 2006 Movement Disorder Society</abstract><qualityIndicators><score>5.293</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>3</keywordCount><abstractCharCount>1561</abstractCharCount><pdfWordCount>2293</pdfWordCount><pdfCharCount>13782</pdfCharCount><pdfPageCount>4</pdfPageCount><abstractWordCount>254</abstractWordCount></qualityIndicators><title>A double‐blind placebo‐controlled trial of zonisamide (zonegran) in the treatment of essential tremor</title><genre><json:string>article</json:string></genre><host><volume>22</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>4</total><last>282</last><first>279</first></pages><issn><json:string>0885-3185</json:string></issn><issue>2</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1002/mds.21282</json:string></doi><id>E3463E3594391F8A815E479F37127B652E6B3DA4</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/E3463E3594391F8A815E479F37127B652E6B3DA4/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/E3463E3594391F8A815E479F37127B652E6B3DA4/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/E3463E3594391F8A815E479F37127B652E6B3DA4/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">A double‐blind placebo‐controlled trial of zonisamide (zonegran) in the treatment of essential tremor</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2007</date></publicationStmt><notesStmt><note type="content">*The authors have confirmed with the Editors that their work complies with the Journal's editorial policy on ghostwriting (Mov Disord;20:1536).</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">A double‐blind placebo‐controlled trial of zonisamide (zonegran) in the treatment of essential tremor</title><author><persName><forename type="first">Theresa A.</forename><surname>Zesiewicz</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: University of South Florida, 12901 Bruce B. Downs Boulevard, MDC Box 55, Tampa, FL 33612</p></note><affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</affiliation></author><author><persName><forename type="first">Christopher L.</forename><surname>Ward</surname></persName><roleName type="degree">LMT</roleName><affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</affiliation></author><author><persName><forename type="first">Robert A.</forename><surname>Hauser</surname></persName><roleName type="degree">MD</roleName><affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</affiliation></author><author><persName><forename type="first">Juan</forename><surname>Sanchez‐Ramos</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</affiliation></author><author><persName><forename type="first">Joseph F.</forename><surname>Staffetti</surname></persName><roleName type="degree">MD</roleName><affiliation>Regional Medical Center, Bayonet Pointe, University of South Florida, Tampa, Florida, USA</affiliation></author><author><persName><forename type="first">Kelly L.</forename><surname>Sullivan</surname></persName><roleName type="degree">MSPH</roleName><affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-01-15"></date><biblScope unit="volume">22</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="279">279</biblScope><biblScope unit="page" to="282">282</biblScope></imprint></monogr><idno type="istex">E3463E3594391F8A815E479F37127B652E6B3DA4</idno><idno type="DOI">10.1002/mds.21282</idno><idno type="ArticleID">MDS21282</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2007</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="fr"><p>Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double‐blind placebo‐controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 ± 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn–Tolosa–Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI‐C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 ± 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (−0.50 ± 0.72 vs. 0.30 ± 0.79 m/s2; P = 0.03). On the CGI‐C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was “minimally improved.” Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry. © 2006 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>zonegran</term></item><item><term>zonisamide</term></item><item><term>essential tremor</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2006-07-14">Received</change><change when="2006-09-21">Registration</change><change when="2007-01-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/E3463E3594391F8A815E479F37127B652E6B3DA4/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="20"><doi origin="wiley" registered="yes">10.1002/mds.v22:2</doi><numberingGroup><numbering type="journalVolume" number="22">22</numbering><numbering type="journalIssue">2</numbering></numberingGroup><coverDate startDate="2007-01-15">15 January 2007</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="270" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.21282</doi><idGroup><id type="unit" value="MDS21282"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2006 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2006-07-14"></event><event type="manuscriptRevised" date="2006-09-19"></event><event type="manuscriptAccepted" date="2006-09-21"></event><event type="publishedOnlineEarlyUnpaginated" date="2006-12-05"></event><event type="firstOnline" date="2006-12-05"></event><event type="publishedOnlineFinalForm" date="2007-01-29"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">279</numbering><numbering type="pageLast">282</numbering></numberingGroup><correspondenceTo>University of South Florida, 12901 Bruce B. Downs Boulevard, MDC Box 55, Tampa, FL 33612</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS21282.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="9"></count><count type="wordTotal" number="2559"></count></countGroup><titleGroup><title type="main" xml:lang="en">A double‐blind placebo‐controlled trial of zonisamide (zonegran) in the treatment of essential tremor<link href="#fn"></link></title><title type="short" xml:lang="en">Trial of Zonisamide</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2 #af3 #af4 #af5" corresponding="yes"><personName><givenNames>Theresa A.</givenNames><familyName>Zesiewicz</familyName><degrees>MD</degrees></personName><contactDetails><email>tzesiewi@hsc.usf.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1 #af2 #af4"><personName><givenNames>Christopher L.</givenNames><familyName>Ward</familyName><degrees>LMT</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1 #af2 #af3 #af4 #af5"><personName><givenNames>Robert A.</givenNames><familyName>Hauser</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1 #af2 #af4 #af5"><personName><givenNames>Juan</givenNames><familyName>Sanchez‐Ramos</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Joseph F.</givenNames><familyName>Staffetti</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1 #af2 #af4"><personName><givenNames>Kelly L.</givenNames><familyName>Sullivan</familyName><degrees>MSPH</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="US" type="organization"><unparsedAffiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="US" type="organization"><unparsedAffiliation>Regional Medical Center, Bayonet Pointe, University of South Florida, Tampa, Florida, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">zonegran</keyword><keyword xml:id="kwd2">zonisamide</keyword><keyword xml:id="kwd3">essential tremor</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="fr"><title type="main">Abstract</title><p>Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double‐blind placebo‐controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 ± 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn–Tolosa–Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI‐C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 ± 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (−0.50 ± 0.72 vs. 0.30 ± 0.79 m/s<sup>2</sup>; <i>P</i> = 0.03). On the CGI‐C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was “minimally improved.” Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry. © 2006 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn"><p>The authors have confirmed with the Editors that their work complies with the Journal's editorial policy on ghostwriting (Mov Disord;20:1536).</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>A double‐blind placebo‐controlled trial of zonisamide (zonegran) in the treatment of essential tremor</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Trial of Zonisamide</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>A double‐blind placebo‐controlled trial of zonisamide (zonegran) in the treatment of essential tremor</title></titleInfo><name type="personal"><namePart type="given">Theresa A.</namePart><namePart type="family">Zesiewicz</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</affiliation><description>Correspondence: University of South Florida, 12901 Bruce B. Downs Boulevard, MDC Box 55, Tampa, FL 33612</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christopher L.</namePart><namePart type="family">Ward</namePart><namePart type="termsOfAddress">LMT</namePart><affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Robert A.</namePart><namePart type="family">Hauser</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Juan</namePart><namePart type="family">Sanchez‐Ramos</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Joseph F.</namePart><namePart type="family">Staffetti</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Regional Medical Center, Bayonet Pointe, University of South Florida, Tampa, Florida, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kelly L.</namePart><namePart type="family">Sullivan</namePart><namePart type="termsOfAddress">MSPH</namePart><affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2007-01-15</dateIssued><dateCaptured encoding="w3cdtf">2006-07-14</dateCaptured><dateValid encoding="w3cdtf">2006-09-21</dateValid><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">2</extent><extent unit="tables">2</extent><extent unit="references">9</extent><extent unit="words">2559</extent></physicalDescription><abstract lang="fr">Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double‐blind placebo‐controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 ± 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn–Tolosa–Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI‐C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 ± 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (−0.50 ± 0.72 vs. 0.30 ± 0.79 m/s2; P = 0.03). On the CGI‐C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was “minimally improved.” Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry. © 2006 Movement Disorder Society</abstract><note type="content">*The authors have confirmed with the Editors that their work complies with the Journal's editorial policy on ghostwriting (Mov Disord;20:1536).</note><subject lang="en"><genre>Keywords</genre><topic>zonegran</topic><topic>zonisamide</topic><topic>essential tremor</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>279</start><end>282</end><total>4</total></extent></part></relatedItem><identifier type="istex">E3463E3594391F8A815E479F37127B652E6B3DA4</identifier><identifier type="DOI">10.1002/mds.21282</identifier><identifier type="ArticleID">MDS21282</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2006 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A70 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002A70 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:E3463E3594391F8A815E479F37127B652E6B3DA4
|texte= A double‐blind placebo‐controlled trial of zonisamide (zonegran) in the treatment of essential tremor
}}
| This area was generated with Dilib version V0.6.23. |  |